[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"migraine-with-or-without-aura\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:migraine-with-or-without-aura":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100598439","new-methods-for-evaluating-preventive-migraine-treatment-100598439",false,"NCT07071506","New Methods for Evaluating Preventive Migraine Treatment","Inclusion Criteria:\n\n1. Adults (18-65 years)\n2. ≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria\n3. Known chronic migraine (headache occurring ≥ 15 days per month for \\> 3 months, which on at least 8 days per month has the features of migraine headache) diagnosed before age 65\n4. Eligibility for preventive migraine treatment\n5. Ability to speak and read Danish\n\nExclusion Criteria:\n\n1. Use of onabotulinumtoxinA as preventive migraine treatment during the 4 months before inclusion\n2. Use of other preventive migraine treatment except CGRP antagonists (However, participants are allowed to be on two stable preventive medication (antidepressant, calcium channel blockers, beta blockers or antiepileptic)- 2 months prior to inclusion until end of study), devices for migraine prevention such as transcranial magnetic stimulation and use of nerve blocks 3 months prior to inclusion\n3. Use of opioid or barbiturate medications in the last four weeks before inclusion\n4. Secondary headache disorders including medication overuse headache\n5. Severe psychiatric, vascular disease, or known liver disease\n6. Alcohol abuse or substance abuse\n7. Current or planned pregnancy and lactation","ALL","18 Years","65 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, balanced placebo design, patients with chronic migraine will receive four treatment conditions in a randomized order.",[26,27,28,29],"Migraine","Migraine With or Without Aura","Headache Disorders","Chronic Migraine, Headache",[31,32,33,34,35],"Headache","Chronic migraine","Balanced placebo design","Treatment effects","Adverse events","RECRUITING","2026-05-18",{"date":39,"type":40},"2026-05-19","ACTUAL",{"date":42,"type":40},"2025-06-19",{"date":44,"type":20},"2028-09",{"name":46,"class":47},"University of Aarhus","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100631221","a-study-to-learn-about-the-study-medicine-nurtec-odt-75-mg-after-it-is-released-into-the-markets-in-korea-100631221","NCT07497854","A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea","A Post-marketing Surveillance (PMS) Study to Evaluate the Safety and Effectiveness of NURTEC® ODT 75 mg (Rimegepant Sulfate) in Adult Migraine Patients in Korea.","Rimegepant PMS","Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n1. Subjects aged 19 years or older\n2. Subjects who administered NURTEC® ODT 75 mg (Rimegepant sulfate) according to the approved label\n3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.","19 Years",{"count":58,"type":20},3000,"OBSERVATIONAL","The purpose of this study is to evaluate safety and effectiveness of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine during the PMS period as required by the Korean ministry of food and drug safety (MFDS).",[27],[63,64,65],"Rimegepant sulfate","safety","efficacy","NOT_YET_RECRUITING","2026-05-12",{"date":69,"type":40},"2026-05-15",{"date":71,"type":20},"2026-10-01",{"date":73,"type":20},"2030-08-01",{"name":75,"class":76},"Pfizer","INDUSTRY"]